For example, topical ruxolitinib (marketed as JAK1- and JAK2-selective) and oral preparations of upadacitinib and abrocitinib (both JAK1-selective) are FDA-approved to treat AD [14,15,16]. Here, JAK1 is linked to Alzheimer disease.